Celonic: Soenke Brunswieck appointed as Vice President Cell & Gene Therapy

Swiss biologics CDMO Celonic has appointed Soenke Brunswieck as VP cell & gene therapy to establish the organization’s new portfolio of CDMO services in the cell and gene therapy domain. "Cell & gene therapy represents a new paradigm in human health, with the potential to resolve unmet medical needs to improve patients’ lives through effective and safe advanced therapeutic medicinal products (ATMPs)", said Dr. Konstantin Matentzoglu, CEO at Celonic. "Celonic appointed Soenke specifically for his extensive expertise with platform technologies and manufacturing of cell & gene therapy products". Soenke has a track record as director of business development and project management at PharmaCell (now Lonza Netherlands). Prior to PharmaCell, he was the director of marketing & sales at CellGenix for over 10 years and was responsible for the creation and successful growth of the global market for GMP-reagents used in cell and gene therapy.